Beranda › Karsinoma Epitel Ovarium › Maryland
Uji klinis Karsinoma Epitel Ovarium di Maryland
7 studi untuk Karsinoma Epitel Ovarium mencari peserta di lokasi di Maryland.
Kota di Maryland
Teks studi resmi (Bahasa Inggris)
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
- Research Site, Baltimore
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 1 Okt 2026 · NCT07851025A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- University of Maryland, Baltimore /ID# 275308, Baltimore
- Holy Cross Hospital /ID# 275872, Silver Spring
Menerima pesertaFase 2
Usia 18 ke atas · Wanita · Diperbarui 29 Sep 2026 · NCT06890338AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Research Site, Towson
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 21 Jul 2026 · NCT07218809Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Greater Baltimore Medical Center, Towson
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 2 Jul 2026 · NCT06819007CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- SCRI - Maryland Oncology Hematology, P.A., Annapolis
Menerima pesertaFase 2
Usia 18 ke atas · Wanita · Diperbarui 23 Des 2025 · NCT06690775Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
- Anne Arundel Health System, Annapolis
- Johns Hopkins University School of Medicine, Baltimore
Menerima pesertaStudi observasional
Usia 30 ke atas · Wanita · Diperbarui 16 Sep 2025 · NCT04794322BP1001-A in Patients With Advanced or Recurrent Solid Tumors
- Holy Cross Hospital, Silver Spring
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Mar 2025 · NCT04196257Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.